

FOR IMMEDIATE RELEASE:

BioScience Laboratories Announces Testing Capabilities for NDM-1

Bozeman, Montana, August 16, 2010 — BioScience Laboratories has obtained seven clinical isolates of Carbapenem-Resistant (CR) *Klebsiella pneumoniae* and *Escherichia coli*. These organisms provide a strong model for predicting a product's efficacy against "Super-Bugs," such as the New Delhi metallo- β -lactamase 1 (NDM-1) strain that has aroused recent worldwide concern. Carbapenems are historically used as a last resort for fighting bacterial infections, particularly versus multidrug-resistant Gram-negative species. The five isolates of CR-*Klebsiella pneumoniae* and two isolates of CR-*Escherichia coli* are being used by BioScience Laboratories microbiologists to test products for their in-vitro efficacy as topical antimicrobials or hard-surface disinfectants to provide data predictive of a product's efficacy versus the New Delhi metallo- β -lactamase 1 (NDM-1) strain.

For additional information, contact:

John Dyba
BioScience Laboratories, Inc.
1-877-858-2754
FAX 406-586-7930
jdyba@biosciencelabs.com
www.biosciencelabs.com

BioScience Laboratories, Inc. was founded in 1991 in Bozeman, MT, to provide antimicrobial product testing and result interpretation grounded in science. Bioscience Laboratories Inc. strives to assist its clients in strengthening their current market positions through product testing and aid in the development of new products and new markets. Today, BioScience Laboratories offers a variety of state-of-the-art laboratory services and guidance regarding federal regulatory agency requirements for the healthcare, pharmaceutical, personal care and consumer products markets.

###